Use: Labeled indications
- To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial…
- As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in
Full indications and usage US FDA label
1 INDICATIONS AND USAGE REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events. (1) As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in (1): adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
Contraindications
4 CONTRAINDICATIONS REPATHA is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in REPATHA. Serious hypersensitivity reactions including angioedema have occurred in patients treated with REPATHA [see Warnings and Precautions (5.1)]. Patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in REPATHA. (4)
US FDA labelDosing: Adult
- In adults at increased risk for CV events or with hypercholesterolemia: The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously. (2.1)
- If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen. (2.1)
- In adults and pediatric patients aged 10 years and older with HeFH: The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously. (2.1)
- If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen. (2.1)
- In adults and pediatric patients aged 10 years and older with HoFH: The initial recommended dosage of REPATHA is 420 mg once monthly administered subcutaneously. (2.1)
- The dosage can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. (2.1)
- Patients on lipid apheresis may initiate treatment with 420 mg every 2 weeks to correspond with their apheresis schedule. Administer REPATHA after the apheresis session is complete. (2.1)
- Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be measured as early as 4 weeks after initiation. (2.1)
- REPATHA is available as prefilled single-dose SureClick ® autoinjectors, and prefilled single-dose syringes that …
2.1 Recommended Dosage
2.1 Recommended Dosage In adults at increased risk for CV events or with hypercholesterolemia: The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously [see Dosage and Administration (2.3)]. If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen.
In adults and pediatric patients aged 10 years and older with HeFH: The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously [see Dosage and Administration (2.3)]. If switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen.
In adults and pediatric patients aged 10 years and older with HoFH: The initial recommended dosage of REPATHA is 420 mg once monthly administered subcutaneously [see Dosage and Administration (2.3)]. The dosage can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. Patients on lipid apheresis may initiate treatment with 420 mg every 2 weeks to correspond with their apheresis schedule.
Administer REPATHA after the apheresis session is complete. Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be measured as early as 4 weeks after initiation. When monitoring LDL-C for patients receiving REPATHA 420 mg once monthly, note that LDL-C can vary during the dosing interval in some patients; recommend measuring LDL-C just prior to the next scheduled dose [see Clinical Studies (14)].
2.2 Missed Doses
2.2 Missed Doses If a dose is missed: Within 7 days from the missed dose, instruct the patient to administer REPATHA and resume the patient's original schedule. More than 7 days after the missed dose: For an every 2-week dose, instruct the patient to wait until the next dose on the original schedule. For a once-monthly dose, instruct the patient to administer the dose and start a new schedule based on this date.
2.3 Important Administration Instructions
2.3 Important Administration Instructions REPATHA is available as prefilled single-dose SureClick ® autoinjectors and prefilled single-dose syringes that either contain dry natural rubber (a derivative of latex) in the needle cover or are not made with natural rubber latex [see How Supplied/Storage and Handling (16)]. Consider prescribing a presentation of REPATHA that does not contain dry natural rubber for individuals that are sensitive to latex [see Warnings and Precautions (5.1)].
Train patients and/or caregivers on how to prepare and administer REPATHA, according to the Instructions for Use and instruct them to read and follow the Instructions for Use each time they use REPATHA. Prior to use, allow REPATHA to warm to room temperature for at least 30 minutes for the prefilled single-dose pen, prefilled single-dose SureClick ® autoinjector, or prefilled single-dose syringe if REPATHA has been refrigerated [see How Supplied/Storage and Handling (16)].
Visually inspect REPATHA prior to administration. REPATHA is a clear to opalescent, colorless to pale yellow solution. Do not use if the solution is cloudy, discolored, or contains particles. For use in adult and pediatric patients aged 10 years and older: Administer REPATHA subcutaneously into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated.
Avoid injecting into areas with scars or stretch marks. Rotate injection sites for each administration. The 420 mg dose of REPATHA can be administered: by giving 3 injections consecutively within 30 minutes using the prefilled single-dose pen, prefilled single-dose SureClick ® autoinjector, or prefilled single-dose syringe.
Dosing: Altered kidney function
8.6 Renal Impairment No dose adjustment is needed in patients with renal impairment [see Clinical Pharmacology (12.3)].
Renal Impairment Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of evolocumab. In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m², n = 6), severe renal impairment (eGFR < 30 mL/min/1.73 m², n = 6), or end-stage renal disease (ESRD) receiving hemodialysis (n = 6), exposure to evolocumab after a single 140 mg subcutaneous dose was decreased in patients with severe renal impairment or ESRD receiving hemodialysis.
Reductions in PCSK9 levels in patients with severe renal impairment or ESRD receiving hemodialysis was similar to those with normal renal function [see Use in Specific Populations (8.6)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No dose adjustment is needed in patients with mild to moderate hepatic impairment (Child-Pugh A or B). No data are available in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of REPATHA in combination with diet and other LDL-C-lowering therapies for the treatment of HoFH have been established in pediatric patients aged 10 years and older. Use of REPATHA for this indication is supported by evidence from an adequate and well-controlled trial in adults and pediatric patients aged 13 years and older with HoFH (including 7 pediatric patients treated with REPATHA) and from open-label studies which included an additional 19 pediatric patients aged 11 years and older with HoFH not previously treated with REPATHA [see Adverse Reactions (6.1) and Clinical Studies (14)].
The safety and effectiveness of REPATHA as an adjunct to diet and other LDL-C-lowering therapies for the treatment of HeFH have been established in pediatric patients aged 10 years and older. Use of REPATHA for this indication is based on data from a 24-week, randomized, placebo-controlled, double-blind trial in pediatric patients with HeFH.
In the trial, 104 patients received REPATHA 420 mg subcutaneously once monthly and 53 patients received placebo; 39 patients (25%) were 10 to 11 years of age [see Adverse Reactions (6.1) and Clinical Studies (14)]. The safety and effectiveness of REPATHA have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In controlled trials, 11,112 (45%) patients treated with REPATHA were ≥ 65 years old and 2,130 (9%) were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Administration
2.3 Important Administration Instructions REPATHA is available as prefilled single-dose SureClick ® autoinjectors and prefilled single-dose syringes that either contain dry natural rubber (a derivative of latex) in the needle cover or are not made with natural rubber latex [see How Supplied/Storage and Handling (16) ] . Consider prescribing a presentation of REPATHA that does not contain dry natural rubber for individuals that are sensitive to latex [see Warnings and Precautions (5.1) ] . Train patients and/or caregivers on how to prepare and administer REPATHA, according to the Instructions for Use and instruct them to read and follow the Instructions for Use each time they use REPATHA. Prior to use, allow REPATHA to warm to room temperature for at least 30 minutes for the prefilled single-dose pen, prefilled single-dose SureClick ® autoinjector, or prefilled single-dose syringe if REPATHA has been refrigerated [see How Supplied/Storage and Handling (16) ] . Visually inspect REPATHA prior to administration. REPATHA is a clear to opalescent, colorless to pale yellow solution. Do not use if the solution is cloudy, discolored, or contains particles. For use in adult and pediatric patients aged 10 years and older: Administer REPATHA subcutaneously into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Avoid injecting into areas with scars or stretch marks. Rotate injection sites for each administration. The 420 mg dose of REPATHA can be administered: by giving 3 injections consecutively within 30 minutes using the prefilled single-dose pen, prefilled single-dose SureClick ® autoinjector, or prefilled single-dose syringe.
US FDA labelDosage forms
Philippines
- Solution for injection: 140 mg/mL
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Evolocumab as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
RepathaEvolocumab | 140 mg/mL Solution for Injection (SC)Single use. 1 mL-net content Type I pre-filled glass syringe with stainless 27 gauge needle assembled in an auto-injector pen (Box of 1's) | RxVAT-exempt | Amgen Manufacturing LimitedU.S.A. | Zuellig Pharma Corporation | BR-1266 | Apr 23, 2028 | |
RepathaEvolocumab | 140 mg/mL Solution for Injection (SC)Single use. 1 mL-net content Type I pre-filled glass syringe with bromobutyl elastomeric, polysterene plunger rod and stainless 27 gauge needle covered with an elastomeric needle shield (Box of 1's) | RxVAT-exempt | Amgen Manufacturing LimitedU.S.A. | Zuellig Pharma Corporation | BR-1267 | Apr 23, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS REPATHA injection is a clear to opalescent, colorless to pale yellow solution available as follows: 140 mg/mL solution in a prefilled single-dose pen 140 mg/mL solution in a prefilled single-dose SureClick ® autoinjector 140 mg/mL solution in a prefilled single-dose syringe Injection (3): 140 mg/mL solution prefilled single-dose pen 140 mg/mL solution prefilled single-dose SureClick ® autoinjector 140 mg/mL solution prefilled single-dose syringe
Warnings/Precautions
Warnings and precautions (US label) US FDA label
5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Angioedema has occurred. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with REPATHA, treat according to the standard of care, and monitor until signs and symptoms resolve. (5.1) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including angioedema, have been reported in patients treated with REPATHA.
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with REPATHA, treat according to the standard of care, and monitor until signs and symptoms resolve. REPATHA is contraindicated in patients with a history of serious hypersensitivity reactions to evolocumab or any excipient in REPATHA [see Contraindications (4)].
The prefilled single-dose SureClick ® autoinjector and prefilled single-dose syringe presentations of REPATHA that contain dry natural rubber (a derivative of latex) in the needle cover may cause an allergic reaction in individuals sensitive to latex. Instruct patients to inform their healthcare provider if they are sensitive to latex.
Consider prescribing a presentation of REPATHA that does not contain dry natural rubber for individuals that are sensitive to latex [see How Supplied/Storage and Handling (16)].
Adverse reactions
The following adverse reactions are also discussed in other sections of the label: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Common (> 5% of patients treated with REPATHA and more frequently than placebo) adverse reactions in adults with: Hypercholesterolemia: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions. (6) Established CV Disease: diabetes mellitus, nasopharyngitis and upper respiratory tract infection.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adverse Reactions in Adults with Hypercholesterolemia The data described below reflect exposure to REPATHA in 8 placebo-controlled trials that included 2,651 patients treated with REPATHA, including 557 exposed for 6 months and 515 exposed for 1 year (median treatment duration of 12 weeks).
The mean age of the population was 57 years, 49% of the population were female, 85% White, 6% Black or African American, 8% Asian, and 2% other races. Adverse Reactions in a 52 - Week Controlled Trial In a 52-week, double-blind, randomized, placebo-controlled trial, 599 patients received 420 mg of REPATHA subcutaneously once monthly [see Clinical Studies (14)].
The mean age was 56 years (range: 22 to 75 years), 23% were older than 65 years, 52% female, 80% White, 8% Black or African American, 6% Asian; 6% identified as Hispanic or Latino ethnicity. Adverse reactions reported in at least 3% of REPATHA-treated patients, and more frequently than in placebo-treated patients are shown in Table 1.
Adverse reactions led to discontinuation of treatment in 2.2% of REPATHA-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to REPATHA treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for REPATHA and placebo, respectively). Table 1.
Adverse Reactions Occurring in ≥ 3% of REPATHA-treated Patients and More Frequently than with Placebo in a 52-Week Trial Placebo (N = 302) % REPATHA (N = 599) % Nasopharyngitis 9.6 10.5 Upper respiratory tract infection 6.3 9.3 Influenza 6.3 7.5 Back pain 5.6
6.2 Injection
6.2 Injection site reactions includes erythema, pain, bruising 5.0 5.7 Cough 3.6 4.5 Urinary tract infection 3.6 4.5 Sinusitis 3.0 4.2 Headache 3.6 4.0 Myalgia 3.0 4.0 Dizziness 2.6 3.7 Musculoskeletal pain 3.0 3.3 Hypertension 2.3 3.2 Diarrhea 2.6 3.0 Gastroenteritis 2.0 3.0 Adverse Reactions in Seven Pooled 12 - Week Controlled Trials In seven pooled 12-week, double-blind, randomized, placebo-controlled trials, 993 patients received 140 mg of REPATHA subcutaneously every 2 weeks and 1,059 patients received 420 mg of REPATHA subcutaneously monthly. The mean age was 57 years (range: 18 to 80 years), 29% were older than 65 years, 49% female, 85% White, 5% Black or African American, 9% Asian; 5% identified as Hispanic or Latino ethnicity.
Adverse reactions reported in at least 1% of REPATHA-treated patients, and more frequently than in placebo-treated patients, are shown in Table 2. Table 2. Adverse Reactions Occurring in ≥ 1% of REPATHA-treated Patients and More Frequently than with Placebo in Pooled 12-Week Trials Placebo (N = 1,224) % REPATHA 140 mg every 2 weeks and 420 mg once monthly combined (N = 2,052) % Nasopharyngitis 3.9 4.0 Back pain 2.2 2.3 Upper respiratory tract infection 2.0 2.1 Arthralgia 1.6 1.8 Nausea 1.2 1.8 Fatigue 1.0 1.6 Muscle spasms 1.2 1.3 Urinary tract infection 1.2 1.3 Cough 0.7 1.2 Influenza 1.1 1.2 Contusion 0.5 1.0 Adverse Reactions in Eight Pooled Controlled Trials (Seven 12 - Week Trials and One 52 - Week Trial) The adverse reactions described below are from a pool of the 52-week trial and seven 12-week trials.
The mean and median exposure durations of REPATHA in this pool of eight trials were 20 weeks and 12 weeks, respectively. Local Injection Site Reactions Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.
The proportions of patients who discontinued treatment due to local injection site reactions in REPATHA-treated patients and placebo-treated patients were 0.1% and 0%, respectively. Hypersensitivity Reactions Hypersensitivity reactions occurred in 5.1% and 4.7% of REPATHA-treated and placebo-treated patients, respectively.
The most common hypersensitivity reactions were rash (1.0% versus 0.5% for REPATHA and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). Adverse Reactions in the CV Outcomes Trials Trial 1 (FOURIER) In a double-blind, randomized, placebo-controlled CV outcomes trial in patients with established atherosclerotic cardiovascular disease (ASCVD), 27,525 patients received at least one dose of REPATHA or placebo [see Clinical Studies (14)].
The mean age was 62.5 years (range: 40 to 86 years), 45% were 65 years or older, 9% were 75 years or older, 25% female, 85% White, 10% Asian, and 2% Black or African American; 8% identified as Hispanic or Latino ethnicity. Patients were exposed to REPATHA or placebo for a median of 24.8 months; 91% of patients were exposed for ≥ 12 months, 54% were exposed for ≥ 24 months and 5% were exposed for ≥ 36 months.
The safety profile of REPATHA in this trial was generally consistent with the safety profile described above in the 12- and 52-week controlled trials involving patients with hypercholesterolemia. Common adverse reactions (> 5% of patients treated with REPATHA and occurring more frequently than placebo) included diabetes mellitus (8.8% REPATHA, 8.2% placebo), nasopharyngitis (7.8% REPATHA, 7.4% placebo), and upper respiratory tract infection (5.1% REPATHA, 4.8% placebo).
Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with REPATHA compared with 7.7% in patients that received placebo. Trial 2 (VESALIUS-CV) In another double-blind, randomized, placebo-controlled cardiovascular outcomes trial in patients at high CV risk without a prior myocardial infarction or stroke, including those with ASCVD or diabetes mellitus with additional risk factors for CV disease, 12,196 patients received at least one dose of REPATHA (6, 102) or placebo (6, 094) [see Clinical Studies (14)].
The mean age was 65 years (range: 46 to 86 years), 56% were 65 years or older, 10% were 75 years or older, 43% female, 93% White, 4% Asian, 2% Black or African American, 0.4% American Indian or Alaska Native, and < 0.1% Native Hawaiian or Other Pacific Islander; 17% identified as Hispanic or Latino ethnicity. A total of 6,102 patients were exposed to REPATHA for a median of 53 months; 84% of patients were exposed for ≥ 36 months, 62% were exposed for ≥ 48 months, and 22% were exposed for ≥ 60 months.
The safety profile of REPATHA in this trial was consistent with the known safety profile of REPATHA. Adverse Reactions in Pediatric Patients with HeFH In a 24-week, randomized, placebo-controlled, double-blind trial of 157 pediatric patients with HeFH, 104 patients received 420 mg REPATHA subcutaneously once monthly [see Clinical Studies (14)].
The mean age was 13.7 years (range: 10 to 17 years), 56% were female, 85% White, 1% Black or African American, 1% Asian, and 13% other; 8% identified as Hispanic or Latino ethnicity. Common adverse reactions (> 5% of patients treated with REPATHA and occurring more frequently than placebo) included: Nasopharyngitis (12% versus 11%) Headache (11% versus 2%) Oropharyngeal pain (7% versus 0%) Influenza (6% versus 4%) Upper respiratory tract infection (6% versus 2%) One hundred fifty (150) of these 157 patients continued on to an 80-week open-label treatment period; 67% (n = 101) of patients continued REPATHA treatment, and 33% (n = 49) of patients switched from placebo to REPATHA.
The safety profile reported in these patients was consistent with the description above for pediatric patients with HeFH in the double-blind treatment period. Adverse Reactions in Adults and Pediatric Patients with HoFH In a 12-week, double-blind, randomized, placebo-controlled trial of 49 patients with HoFH, 33 patients received 420 mg of REPATHA subcutaneously once monthly [see Clinical Studies (14)].
The mean age was 31 years (range: 13 to 57 years), 49% were female, 90% White, 4% Asian, and 6% other. The adverse reactions that occurred in at least two (6.1%) REPATHA-treated patients, and more frequently than in placebo-treated patients, included: Upper respiratory tract infection (9.1% versus 6.3%) Influenza (9.1% versus 0%) Gastroenteritis (6.1% versus 0%) Nasopharyngitis (6.1% versus 0%) In a multicenter, open-label 5-year extension study, 106 patients with HoFH, including 14 pediatric patients, received 420 mg of REPATHA subcutaneously once monthly or every 2 weeks [see Clinical Studies (14)].
The mean age was 34 years (range: 13 to 68 years), 51% were female, 80% White, 12% Asian, 1% Native American, and 7% other; 5% identified as Hispanic or Latino ethnicity. No new adverse reactions were observed during the open-label extension study.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following additional adverse reactions have been identified during post-approval use of REPATHA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity reactions: Angioedema Influenza-like illness
Adverse reaction frequency tables (US label) US FDA label
| Placebo (N = 302) % | REPATHA (N = 599) % | |
|---|---|---|
| Nasopharyngitis | 9.6 | 10.5 |
| Upper respiratory tract infection | 6.3 | 9.3 |
| Influenza | 6.3 | 7.5 |
| Back pain | 5.6 | 6.2 |
| Injection site reactionsincludes erythema, pain, bruising | 5.0 | 5.7 |
| Cough | 3.6 | 4.5 |
| Urinary tract infection | 3.6 | 4.5 |
| Sinusitis | 3.0 | 4.2 |
| Headache | 3.6 | 4.0 |
| Myalgia | 3.0 | 4.0 |
| Dizziness | 2.6 | 3.7 |
| Musculoskeletal pain | 3.0 | 3.3 |
| Hypertension | 2.3 | 3.2 |
| Diarrhea | 2.6 | 3.0 |
| Gastroenteritis | 2.0 | 3.0 |
| Placebo (N = 1,224) % | REPATHA140 mg every 2 weeks and 420 mg once monthly combined (N = 2,052) % | |
|---|---|---|
| Nasopharyngitis | 3.9 | 4.0 |
| Back pain | 2.2 | 2.3 |
| Upper respiratory tract infection | 2.0 | 2.1 |
| Arthralgia | 1.6 | 1.8 |
| Nausea | 1.2 | 1.8 |
| Fatigue | 1.0 | 1.6 |
| Muscle spasms | 1.2 | 1.3 |
| Urinary tract infection | 1.2 | 1.3 |
| Cough | 0.7 | 1.2 |
| Influenza | 1.1 | 1.2 |
| Contusion | 0.5 | 1.0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from clinical trials and postmarketing reports on REPATHA use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no effects on pregnancy or neonatal/infant development when monkeys were subcutaneously administered evolocumab from organogenesis through parturition at dose exposures up to 12 times the exposure at the maximum recommended human dose of 420 mg every month.
In a similar study with another drug in the PCSK9 inhibitor antibody class, humoral immune suppression was observed in infant monkeys exposed to that drug in utero at all doses. The exposures where immune suppression occurred in infant monkeys were greater than those expected clinically. No assessment for immune suppression was conducted with evolocumab in infant monkeys.
Measurable evolocumab serum concentrations were observed in the infant monkeys at birth at comparable levels to maternal serum, indicating that evolocumab, like other IgG antibodies, crosses the placental barrier. Monoclonal antibodies are transported across the placenta in increasing amounts especially near term; therefore, evolocumab has the potential to be transmitted from the mother to the developing fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Report pregnancies by contacting Amgen at 1-800-77-AMGEN (1-800-772-6436) or https://wwwext.amgen.com/products/global-patient-safety/adverse-event-reporting.
Data Animal Data In cynomolgus monkeys, no effects on embryo-fetal or postnatal development (up to 6 months of age) were observed when evolocumab was dosed during organogenesis to parturition at 50 mg/kg once every 2 weeks by the subcutaneous route at exposures 30- and 12-fold the recommended human doses of 140 mg every 2 weeks and 420 mg once monthly, respectively, based on plasma AUC. No test of humoral immunity in infant monkeys was conducted with evolocumab.
Mechanism of action
12.1 Mechanism of Action Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Following single subcutaneous administration of 140 mg or 420 mg of evolocumab, maximum suppression of circulating unbound PCSK9 occurred by 4 hours. Unbound PCSK9 concentrations returned toward baseline when evolocumab concentrations decreased below the limit of quantitation. Maximum LDL-C reduction occurred by 2 weeks after a single-dose of 140 mg of evolocumab and by 3 weeks after a single-dose of 420 mg of evolocumab.
Pharmacokinetics
REPATHA was estimated to have an effective half-life of 11 to 17 days.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Evolocumab exhibits non-linear kinetics as a result of binding to PCSK9. Administration of the 140 mg dose in healthy volunteers resulted in a C max mean of 18.6 µg/mL and AUC last mean of 188 day∙µg/mL. Administration of the 420 mg dose in healthy volunteers resulted in a C max mean of 59.0 µg/mL and AUC last mean of 924 day∙µg/mL.
Following a single 420 mg intravenous dose, the mean systemic clearance was estimated to be 12 mL/hr. An approximate 2- to 3-fold accumulation was observed in trough serum concentrations (C min 7.21 µg/mL) following 140 mg doses administered subcutaneously every 2 weeks or following 420 mg doses administered subcutaneously monthly (C min 11.2 µg/mL), and serum trough concentrations approached steady-state by 12 weeks of dosing.
Absorption Following a single subcutaneous dose of 140 mg or 420 mg evolocumab administered to healthy adults, median peak serum concentrations were attained in 3 to 4 days, and estimated absolute bioavailability was 72%. Distribution Following a single 420 mg intravenous dose, the mean steady-state volume of distribution was estimated to be 3.3 L.
Elimination Two elimination phases were observed for REPATHA. At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination of REPATHA is largely through a non-saturable proteolytic pathway. REPATHA was estimated to have an effective half-life of 11 to 17 days.
Specific Populations The pharmacokinetics of evolocumab were not affected by age, gender, race, or creatinine clearance across all approved populations [see Use in Specific Populations (8.5)]. The exposure of evolocumab decreased with increasing body weight. These differences are not clinically meaningful. Pediatric Patients The pharmacokinetics of REPATHA were evaluated in 103 pediatric patients aged 10 to 17 years with HeFH (Trial 7) [see Use in Specific Populations (8.4) and Clinical Studies (14)].
Following subcutaneous administration of 420 mg REPATHA once monthly, mean trough serum concentrations were 22.4 mcg/mL and 25.8 mcg/mL over the Week 12 and Week 24 time points, respectively. The pharmacokinetics of REPATHA were evaluated in 12 pediatric patients aged 11 to 17 years with HoFH (Trial 10) [see Use in Specific Populations (8.4) and Clinical Studies (14)].
Following subcutaneous administration of 420 mg REPATHA once monthly, mean serum trough concentrations were 20.3 mcg/mL and 17.6 mcg/mL at Week 12 and Week 80, respectively. Renal Impairment Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of evolocumab.
In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m², n = 6), severe renal impairment (eGFR < 30 mL/min/1.73 m², n = 6), or end-stage renal disease (ESRD) receiving hemodialysis (n = 6), exposure to evolocumab after a single 140 mg subcutaneous dose was decreased in patients with severe renal impairment or ESRD receiving hemodialysis. Reductions in PCSK9 levels in patients with severe renal impairment or ESRD receiving hemodialysis was similar to those with normal renal function [see Use in Specific Populations (8.6)].
Hepatic Impairment Following a single 140 mg subcutaneous dose of evolocumab in patients with mild or moderate hepatic impairment, a 20-30% lower mean C max and 40-50% lower mean AUC were observed as compared to healthy patients [see Use in Specific Populations (8.7)]. Drug Interaction Studies An approximately 20% decrease in the C max and AUC of evolocumab was observed in adult patients co-administered a high-intensity statin regimen.
This difference is not clinically meaningful.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. REPATHA · Amgen USA Inc. [US FDA-approved label, version 33, October 12, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd61e902-166d-4aa6-9f3c-a18c1008d07e
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .